Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) FCF Margin (2016 - 2026)

Ani Pharmaceuticals' FCF Margin history spans 16 years, with the latest figure at 16.96% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 165.0% to 16.96% in Q4 2025 year-over-year; TTM through Dec 2025 was 20.85%, a 1052.0% increase, with the full-year FY2025 number at 20.85%, up 1052.0% from a year prior.
  • FCF Margin hit 16.96% in Q4 2025 for Ani Pharmaceuticals, up from 16.66% in the prior quarter.
  • Over the last five years, FCF Margin for ANIP hit a ceiling of 178.3% in Q1 2021 and a floor of 29.77% in Q1 2022.
  • Historically, FCF Margin has averaged 15.93% across 5 years, with a median of 15.03% in 2024.
  • Biggest five-year swings in FCF Margin: surged 17796bps in 2021 and later crashed -20807bps in 2022.
  • Tracing ANIP's FCF Margin over 5 years: stood at 20.58% in 2021, then surged by 76bps to 4.93% in 2022, then soared by 885bps to 38.74% in 2023, then tumbled by -60bps to 15.31% in 2024, then increased by 11bps to 16.96% in 2025.
  • Business Quant data shows FCF Margin for ANIP at 16.96% in Q4 2025, 16.66% in Q3 2025, and 33.97% in Q2 2025.